Methadone and Buprenorphine as Medication for Addiction Treatment Diversely Affect Inflammation and Craving Depending on Their Doses
Buprenorphine and methadone are widely used as medication for addiction treatment (MAT) in patients with opioid use disorders. However, there is no compelling evidence of their impact on the immune–endocrine response. Therefore, the aim of this study was to examine the effects of the aforementioned...
Saved in:
| Main Authors: | Christonikos Leventelis, Aristidis S. Veskoukis, Andrea Paola Rojas Gil, Panagiotis Papadopoulos, Maria Garderi, Asimina Angeli, Antzouletta Kampitsi, Maria Tsironi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Pharmacy |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2226-4787/13/2/40 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
COVID-19 Pandemic Detrimentally Affects Craving and Quality of Life in Patients Under Medication-Assisted Treatment with Buprenorphine and Methadone: The Issue of Medication Dose
by: Christonikos Leventelis, et al.
Published: (2024-11-01) -
Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
by: Minna M. Kanervo, et al.
Published: (2023-03-01) -
Memory function in patients with opioid dependence treated with buprenorphine and methadone in comparison with healthy persons
by: Sara Kamali Ardakani, et al.
Published: (2025-05-01) -
Comparing quality of life methadone and buprenorphine for opioid substitution treatment in Iran
by: Ahmad Nemati, et al.
Published: (2025-08-01) -
Quality of life of treated opiate addicts in the methadone maintenance program and those treated with buprenorphine
by: Marinković Mirjana, et al.
Published: (2017-01-01)